Qué cambió
Qué cambióEntre el 14 de septiembre y el 29 de septiembre de 2026, Eli Lilly llevó a cabo varios ensayos clínicos, incluidos estudios de nuevos compuestos y la finalización de un ensayo de Fase 4 para el tratamiento de la diabetes. Estas actividades tienen como objetivo evaluar el potencial terapéutico de agentes experimentales y nuevas indicaciones para medicamentos existentes.

Historial de la empresa
Octubre 2026
ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-10.
- 2026-10-08: Participants receive eloralintide subcutaneously as the experimental intervention. Fuente
- 2026-10-08: Participants receive single doses of LY4268989 in six treatment arms, with high‑fat and fasted states. Fuente
- 2026-10-08: The study enrolls 123 healthy participants and includes four inpatient stays at the clinical research unit. Fuente
- 2026-10-08: The study has four parts: single-ascending dose, multiple-ascending dose, single dose in three periods, and midazolam co‑administration. Fuente
- 2026-10-08: The trial is recruiting participants with overweight or prediabetic conditions to receive the investigational drug Orforglipron orally. Fuente
- 2026-10-08: Participants will receive LY4329090 administered subcutaneously (SC). Fuente
- 2026-10-08: The study includes two parts: Part A lasting about 10 weeks with 5 nights stay and 5 outpatient visits, Part B lasting about 21 weeks with 4 stays totaling 11 nights and 14 outpatient visits. Fuente
- 2026-10-08: The study is a randomized, parallel, double‑masked, basic science interventional study with estimated enrollment of 184 participants. Fuente
- 2026-10-08: The study will enroll 161 participants and is a Phase 2 randomized, open-label, parallel-design intervention study. Fuente
- 2026-10-08: The study will evaluate vepugratinib in adults with low‑grade, intermediate‑risk non‑muscle invasive bladder cancer or low‑grade upper tract urothelial carcinoma. Fuente
- 2026-10-09: The primary purpose of the study is basic science evaluating the safety and tolerability of LY5625575. Fuente
- 2026-10-09: The study will include healthy participants and participants with elevated high-sensitivity C-reactive protein. Fuente
Septiembre 2026
ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-09.
- 2026-09-23: The intervention includes abemaciclib in three formulations: Tablet Test Formulation 1, Oral Granules Test Formulation 2, and Reference Tablet Formulation 1. Fuente
- 2026-09-23: The trial will last about 8 weeks, including screening and follow-up. Fuente
- 2026-09-24: The trial is a phase 2, nonrandomized, sequential, open-label, single‑arm study of mosunetuzumab plus pirtobrutinib in relapsed or refractory Waldenstrom’s Macroglobulinemia. Fuente
- 2026-09-24: Patients must be ≥18 years with measurable Waldenstrom’s Macroglobulinemia and have relapsed or refractory disease after at least one prior line of therapy. Fuente
- 2026-09-24: The total number of cycles administered is 18 for patients with a complete, very good partial or minor response in dosing strategy 1 and 19 in dosing strategy 2. Fuente
- 2026-09-28: The trial is a prospective, single-arm, nonrandomized, open-label, phase I/II study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) in patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases. Fuente
- 2026-09-28: Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. Fuente
- 2026-09-28: The trial intervention included subcutaneous injections of insulin lispro-aabc (also known as LY900014 or Lyumjev) combined with insulin glargine (Basaglar). Fuente
- 2026-09-28: The company's product, baricitinib (Olumiant), was evaluated in a Phase 2 study for the treatment of central centrifugal cicatricial alopecia in adults of African descent. Fuente
- 2026-09-28: In a Phase 2 trial of baricitinib for central centrifugal cicatricial alopecia, 27 participants received at least one dose and 17 completed the 52-week treatment period. Fuente
- 2026-09-29: Eli Lilly and Company is conducting a Phase 1 study to evaluate the tolerability and side effects of the drug LY4057996 in healthy participants and those with Type 1 or Type 2 Diabetes. Fuente
- 2026-09-29: The study arms include experimental groups testing LY4057996 administered subcutaneously or intravenously, alone or in combination with other agents such as Lispro and basal insulin, against placebo and active comparators. Fuente
Los registros mensuales los redacta la IA a partir de los informes y fuentes oficiales verificados de cada mes (en inglés, tal como se extrajeron), y cada línea enlaza su fuente; las líneas argumentales agrupan hechos relacionados entre análisis mediante embeddings vectoriales (Amazon Titan Text Embeddings V2). Contexto provisional, no es asesoramiento de inversión.
Comparables del sector
Comparación con 36 empresas seguidas en Salud (mediana de ingresos +7,2% a/a), según datos XBRL de la SEC.
| Empresa | Últimos ingresos | Ingresos a/a | Margen operativo |
|---|
| ELI Lilly & Co LLY | 24,4 mil M $ | +38,6% | — |
| Unitedhealth Group Inc UNH | 113 mil M $ | -0,4% | 5,8% |
| Mckesson Corp MCK | 111 mil M $ | +7,6% | 1,4% |
| CVS Health Corp CVS | 108 mil M $ | +5,4% | 3,3% |
| Cigna Group CI | 73,7 mil M $ | +5,6% | 3,3% |
| Cardinal Health Inc CAH | 67,5 mil M $ | +5,5% | 1,1% |
| Elevance Health, Inc. ELV | 51,4 mil M $ | +1,4% | 2,5% |
Último periodo reportado por empresa en SEC CompanyFacts (XBRL). Los calendarios fiscales pueden diferir.
Grandes fondos (13F)
| Fondo | Acciones | Valor | Cambio en acciones | Trimestre |
|---|
| BlackRock | 67.936.153 | $78.607.563.355 | +0,6% | T3 2026 |
| State Street | 36.848.565 | $42.636.737.590 | +1,7% | T3 2026 |
| Fidelity (FMR) | 29.959.147 | $34.665.130.320 | +5,3% | T3 2026 |
| Geode Capital Management | 20.556.572 | $23.722.722.425 | +1,2% | T3 2026 |
| Capital Research Global Investors | 16.998.595 | $19.670.092.948 | -18,6% | T3 2026 |
| Norges Bank (Norway's sovereign fund) | 11.471.413 | $13.759.156.895 | — | T2 2026 |
| Wellington Management | 11.048.493 | $12.783.990.282 | +0,5% | T3 2026 |
| Citadel Advisors | 681.483 | $788.530.350 | -27,9% | T3 2026 |
| Two Sigma Investments | 339.220 | $392.504.678 | +317,6% | T3 2026 |
| D. E. Shaw & Co. | 316.379 | $366.075.814 | -36,3% | T3 2026 |
| Millennium Management | 199.938 | $231.344.261 | +9,4% | T3 2026 |
| ARK Investment Management (Cathie Wood) | 107.838 | $124.776.742 | +39,6% | T3 2026 |
| Bridgewater Associates | 94.722 | $109.600.932 | +8,8% | T3 2026 |
| Soros Fund Management | 22.199 | $25.686.019 | 0,0% | T3 2026 |
| T. Rowe Price | 13.383.370 | $15.485.631 | -3,8% | T3 2026 |
De los informes trimestrales 13F-HR de los grandes fondos que seguimos, tal como se presentaron. Los fondos informan hasta 45 días después del cierre del trimestre, por lo que las posiciones pueden haber cambiado. Cambio: frente al trimestre anterior del mismo fondo. No es una recomendación.